CF PharmTech, Inc. (CF PharmTech) announced that it entered into a strategic cooperation agreement with JD Health International Inc. on 20 March 2026, appointing JD Health as the exclusive online launch platform for a series of new products in respiratory and rhinology therapeutics over the next three years.

Under the agreement, JD Health will: 1) Deploy its e-commerce and supply-chain infrastructure to support online sales and patient-service operations for CF PharmTech’s upcoming products; 2) Leverage its prescription‐management and patient-administration capabilities to accelerate commercialization efficiency; 3) Collaborate with CF PharmTech on internet-based chronic-disease management models.

CF PharmTech’s pipeline spans allergic rhinitis, chronic rhinosinusitis, asthma and chronic obstructive pulmonary disease, supplemented by programs targeting pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections and central nervous system disorders. The company combines small-molecule and small-nucleic-acid drugs with inhalation delivery technologies—such as liposomal and siRNA platforms—to enhance efficacy-safety profiles through localized administration.

The board of CF PharmTech states that the partnership is expected to improve patient accessibility and bolster commercialization efficiency amid China’s large, long-term respiratory patient base. The agreement does not constitute a notifiable transaction under Hong Kong listing rules.

Shareholders and potential investors are advised to exercise caution when dealing in CF PharmTech’s securities.